Login to Your Account



Potential $1B for Three Compounds

Synta Lands Preclinical CRACM Deal with Roche, $25M Up Front

By Jennifer Boggs


Monday, January 5, 2009
Synta Pharmaceuticals Corp. ended 2008 on a high note, inking a potentially lucrative early stage deal with F. Hoffmann-La Roche Ltd. for up to three compounds targeting calcium release-activated calcium (CRAC) modulator channels for treating inflammatory diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription